8-K: Vicarious Surgical Reports Q4 and Full Year 2023 Results, Narrows 2024 Cash Burn Guidance

Vicarious Surgical announced its fourth quarter and full year 2023 financial results, highlighting progress on its Version 1.0 surgical system and narrowing its 2024 cash burn guidance.

Summary

• Vicarious Surgical reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company is developing a next-generation surgical robot system.
• They are transitioning from their Beta 2 system to the highly anticipated Version 1.0 product.
• The company achieved its full year 2023 cash burn objective of $63.4 million.
• They have narrowed their full year 2024 cash burn guidance to approximately $50 million.
• Vicarious Surgical has signed a fourth major U.S. hospital system agreement with Intermountain Health, bringing their total partner hospitals to over 250.
• They successfully executed a $47 million equity follow-on offering.
• The company expects to complete the integration of their Version 1.0 system in the fall of 2024.
• Operating expenses for the fourth quarter of 2023 were $15.5 million, a decrease of 25% compared to the same period in 2022.
• The adjusted net loss for the fourth quarter was $14.6 million, or a loss of $0.07 per share.
• Operating expenses for the full year of 2023 were $80.7 million, a 1% increase compared to 2022.
• The adjusted net loss for the full year of 2023 was $76.3 million, or a loss of $0.52 per share.
• The company had $98.2 million in cash and investments as of December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's progress in system development, reduced cash burn, and successful equity offering, although the delay in system integration and continued losses temper the overall outlook.

Positives

• The company successfully reduced its cash burn rate in 2023 and expects further reduction in 2024.
• Vicarious Surgical has expanded its hospital partnerships, indicating growing market interest.
• The successful equity offering has extended the company's cash runway.
• There was a significant decrease in operating expenses in the fourth quarter of 2023.
• The adjusted net loss per share improved in both the fourth quarter and full year of 2023 compared to 2022.

Negatives

• The company experienced a GAAP net loss of $71.1 million for the full year of 2023, compared to a net income of $5.2 million in 2022.
• The company is still experiencing significant losses, although they are improving.
• The integration of the Version 1.0 system has been delayed to the fall of 2024.

Risks

• The company's ability to obtain regulatory approval for its surgical system is a risk.
• The company's ability to compete with other companies in the surgical robotics market is a risk.
• The company's ability to raise additional financing in the future is a risk.
• Economic downturns and market conditions could adversely affect the company's business.

Future Outlook

Vicarious Surgical is focused on completing the integration of its Version 1.0 system in the fall of 2024 and expects a cash burn of approximately $50 million for the full year 2024.

Management Comments

• Adam Sachs, Co-Founder and CEO, stated that they made meaningful progress transitioning their Beta 2 surgical system into their Version 1.0 product in 2023.
• Adam Sachs also mentioned that they ended the year with a more resilient business structure, a defined regulatory strategy, and just under $100 million in cash and investments.

Industry Context

The announcement reflects the ongoing development and competition in the surgical robotics industry, where companies are striving to improve patient outcomes and reduce healthcare costs. Vicarious Surgical is positioning itself as a next-generation player in this space.

Comparison to Industry Standards

• Vicarious Surgical's cash burn is typical for a pre-revenue medical device company in the development phase.
• Companies like Intuitive Surgical, the leader in surgical robotics, have established a strong market presence, but Vicarious Surgical is targeting a different segment with its unique approach.
• Other companies such as Medtronic and Stryker also have surgical robotics programs, but Vicarious Surgical's focus on minimally invasive surgery with human-like robots differentiates it.
• The company's partnership with over 250 hospitals is a positive sign, but it will need to demonstrate clinical efficacy and commercial viability to compete effectively.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the reduced cash burn and progress on the Version 1.0 system.
• Employees may be impacted by the company's focus on capital efficiency.
• Hospital partners may be interested in the progress of the Version 1.0 system.
• Customers (surgeons and patients) will be impacted by the availability of the new system.

Next Steps

• The company plans to conduct cadaveric testing of the Version 1.0 system in the spring of 2024.
• They aim to complete the integration of the Version 1.0 system in the fall of 2024.

Key Dates

Keywords

surgical robotics, medical devices, financial results, cash burn, equity offering, hospital partnerships, regulatory approval, operating expenses, net loss, Version 1.0 system